COMMUNIQUÉS West-GlobeNewswire

Polaryx Therapeutics Announces Approval to List Common Stock on Nasdaq
30/01/2026
PARAMUS, NJ, Jan. 30, 2026 (GLOBE NEWSWIRE) -- Polaryx Therapeutics (“Polaryx” or the “Company”) a clinical-stage biotechnology company dedicated to the discovery, development, and commercialization of novel, disease- [...]
Communiqué de presse : Le CHMP recommande l'approbation du Rezurock de Sanofi dans l’UE pour le traitement de la maladie chronique du greffon contre l’hôte
30/01/2026
Le CHMP recommande l'approbation du Rezurock de Sanofi dans l’UE pour le traitement de la maladie chronique du greffon contre l’hôte La recommandation s’appuie sur les résultats de sécurité et d’efficacité de plusieurs [...]
Regeneron Reports Fourth Quarter and Full Year 2025 Financial and Operating Results
30/01/2026
Fourth quarter 2025 revenues increased 3% to $3.9 billion versus fourth quarter 2024; full year 2025 revenues increased 1% to $14.3 billion versus 2024 Fourth quarter 2025 Dupixent ® global net sales (recorded by Sanofi [...]
Orion publishes Financial Statement Release for 2025 and holds a webcast on 12 February 2026
30/01/2026
ORION CORPORATION PRESS RELEASE 30 JANUARY 2026 at 9.30 EET Orion publishes Financial Statement Release for 2025 and holds a webcast on 12 February 2026 Orion will publish Financial Statement Release for 2025 on [...]
PhenQ 2026: OTC appetite suppressant search analysis for phentermine alternatives
30/01/2026
New YORK City, NY, Jan. 30, 2026 (GLOBE NEWSWIRE) -- Visit PhenQ Official Website Here TL;DR Summary: Most people are reluctant to discuss weight reduction because it is such a delicate subject. The majority of people [...]
Lexicon Announces Pricing of Approximately $94.6 Million Public Offering and Concurrent Private Placement
30/01/2026
THE WOODLANDS, Texas, Jan. 30, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) (“ Lexicon ”) today announced the pricing of its previously announced underwritten public offering of 32,000,000 [...]
Idorsia to present long-term lucerastat data and kidney biopsy results at WORLDSymposium
30/01/2026
Data from up to 42 months of treatment reinforce lucerastat’s potential as a first-in-class oral substrate reduction therapy addressing key unmet needs across the Fabry population The company is finalizing the [...]
Vaxcyte Announces Pricing of $550 Million Public Offering
30/01/2026
SAN CARLOS, Calif., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company, announced today the pricing of an underwritten public offering of common stock. Vaxcyte is [...]
Vaxcyte Announces Commencement of Proposed Public Offering of Common Stock and Pre-Funded Warrants
29/01/2026
SAN CARLOS, Calif., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company, today announced that it has commenced an underwritten public offering of $500,000,000 of [...]
Focus ADHD Expands Online Psychiatric Services to Adults Across Iowa
29/01/2026
DES MOINES, Iowa, Jan. 29, 2026 (GLOBE NEWSWIRE) -- Focus ADHD, a premier online psychiatric clinic specializing in adult ADHD treatment, today announced the expansion of its telehealth services to patients throughout [...]
CVRx to Report Fourth Quarter 2025 Financial and Operating Results and Host Conference Call on February 12, 2026
29/01/2026
MINNEAPOLIS, Jan. 29, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions [...]
Park Dental Partners Announces Date for 2026 Annual Shareholders Meeting
29/01/2026
MINNEAPOLIS, Jan. 29, 2026 (GLOBE NEWSWIRE) -- Park Dental Partners, Inc. (NASDAQ: PARK), a leading dental resource organization, today announced that it will hold its annual shareholder meeting on Friday, May 29, 2026 [...]
BioSyent Declares First Quarter 2026 Dividend
29/01/2026
MISSISSAUGA, Ontario, Jan. 29, 2026 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is pleased to announce that its Board of Directors has declared a quarterly dividend of $0.055 per [...]
Harvard Bioscience Announces Strategic Consolidation of Manufacturing Operations to Improve Efficiency and Support Long-Term Growth
29/01/2026
Streamlining production footprint and improving manufacturing efficiency through phased closure of Holliston, MA plant Initiative expected to deliver approximately $3 million in cost savings in 2027 and $4 million in [...]
MediciNova Announces 100 Patients Enrolled in SEANOBI Study Expanded-Access-Program (EAP) Evaluating MN‑166 (ibudilast) in ALS patients
30/01/2026
LA JOLLA, Calif., Jan. 29, 2026 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875 [...]
Altimmune Announces Closing of $75 Million Registered Direct Offering of Common Stock
29/01/2026
GAITHERSBURG, Md., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, announced the closing of its [...]
RECORDATI ANNOUNCES STRATEGIC COLLABORATION WITH MODERNA TO DEVELOP AND COMMERCIALIZE WORLDWIDE mRNA 3927 FOR THE TREATMENT OF PROPIONIC ACIDEMIA
29/01/2026
mRNA-3927 is a strong strategic fit with Recordati’s rare Metabolic portfolio Collaboration combines Moderna’s expertise in mRNA technology for rare metabolic disorders with Recordati’s established global rare disease [...]
CareMed Has Been Selected as a National Specialty Pharmacy Provider for Exdensur (depemokimab-ulaa)
29/01/2026
NEW HYDE PARK, N.Y., Jan. 29, 2026 (GLOBE NEWSWIRE) -- CareMed, an independent specialty pharmacy, has been selected as a pharmacy partner by GSK for Exdensur (depemokimab), indicated for the add-on maintenance [...]
Lexicon Announces Proposed Public Offering of Common Stock
29/01/2026
THE WOODLANDS, Texas, Jan. 29, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) (“ Lexicon ”) today announced that it has commenced an underwritten public offering to offer and sell, subject to [...]

Pages